The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD
Carolin AngendohriD, Christiane Koppe, Diran Agaid HerebianiD, Anne T. SchneideriD, Leonie S. Keysberg, Michael T. Singer, Julian Gilljam, Matthias A. Dille, Johannes Georg BodeiD, Sebastian G. DolliD, Marcus ConradiD, Mihael VucuriD, Tom LueddeiD
Abstract
Metabolic dysfunction-associated steatotic liver disease is an increasingly prevalent condition, representing a major risk factor for the development of progressive chronic liver damage. This can potentially give rise to the development of steatohepatitis and hepatocellular carcinoma (HCC). It is already known, that patients with metabolic dysfunction-associated steatotic liver disease (MASLD) show increased systemic and hepatic iron concentrations as well as perturbed lipid metabolism, suggesting involvement of ferroptotic cell death in the development and progression of MASLD. Consequently, inhibition of ferroptosis represents a potential therapeutic option for patients with MASLD. The aim of this study was to determine whether a liver parenchymal cell specific conditional deletion of the pro-ferroptotic gene acyl-CoA synthetase long-chain family member 4 (ACSL4LPC-KO) can ameliorate the onset and progression of MASLD in mice. To this end, ACSL4LPC-KO and floxed wild-type littermates were fed a choline-deficient high-fat diet over the course of 20 and 40 weeks to monitor the progression of metabolic liver injury as well as the development of metabolic syndrome. In contrast to the recently published studies by Duan et al. [1], our results show no significant differences between ACSL4LPC-KO and WT mice with regard to the development of MASLD or the progression of metabolic syndrome. Furthermore, no differences were observed in metabolic parameters (i.e. weight gain, glucose tolerance test, hepatic steatosis) or MASLD-associated inflammatory response. Our analyses therefore suggest that loss of ACSL4 has no effect on the progression of MASLD induced by choline-deficient high fat diet. The discrepancy between our and previously published results could be due to differences in the diets or the influence of a distinct microbiome, so the results obtained with liver parenchymal cell specific ACSL4 null mice should be taken with caution.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 9
- FWCI
- 6.20
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Role of Long Chain Acyl-CoA Synthetases in MASH-driven Hepatocellular Carcinoma and Ferroptosis
Peyton Classon, Alexander Q. Wixom, … Davide Povero·American Journal of Physiology-Gastrointestinal and Liver PhysiologyPeer-reviewed·Aug 28, 2025
- Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis
Ikki Sakuma, Rafael Calais Gaspar, … Gerald I. Shulman·Proceedings of the National Academy of SciencesPeer-reviewed·May 1, 2025
- TLR4 promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis by a mechanism independent of hepatocytes and inflammatory cells
Eliza Elza Altvater, Daniah Kojh, … Jorge Matías Caviglia·bioRxiv·Sep 25, 2025
- A Host Enzyme Reduces Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Inactivating Intestinal Lipopolysaccharide
Zhiyan Wang, Nore Ojogun, … Mingfang Lu·eLifePeer-reviewed·Oct 14, 2024
- Metabolomic, Lipidomic, and Enterohormone Changes in the Progression from MASLD to MASH
Jaclyn A. Rivas, Alexandria C. Murphy, … Eliseo F. Castillo·MetabolismPeer-reviewed·May 20, 2026
- Inhibition of p107 alleviates liver steatosis by reducing de novo fatty acid synthesis.
Juan Cuñarro, Marta Varela Miguens, … Sulay A. Tovar·bioRxiv·Apr 16, 2026